UBD Antibody

中文名稱：

UBD兔多克隆抗體
貨號：

CSB-PA025435LA01HU
規格：

￥440
圖片：
Immunohistochemistry of paraffin-embedded human kidney tissue using CSB-PA025435LA01HU at dilution of 1:100

Immunofluorescent analysis of HepG2 cells using CSB-PA025435LA01HU at dilution of 1:100 and Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L)
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品名稱：

Rabbit anti-Homo sapiens (Human) UBD Polyclonal antibody
Uniprot No.：

O15205
基因名：

UBD
別名：

Diubiquitin antibody; FAT10 antibody; GABBR1 antibody; UBD 3 antibody; Ubd antibody; UBD_HUMAN antibody; Ubiquitin D antibody; Ubiquitin like protein FAT10 antibody; Ubiquitin-like protein FAT10 antibody
宿主：

Rabbit
反應種屬：

Human
免疫原：

Recombinant Human Ubiquitin D protein (1-165AA)
免疫原種屬：

Homo sapiens (Human)

標記方式：

Non-conjugated

本頁面中的產品，UBD Antibody (CSB-PA025435LA01HU)，的標記方式是Non-conjugated。對于UBD Antibody，我們還提供其他標記。見下表：

標記方式	貨號	產品名稱	應用
HRP	CSB-PA025435LB01HU	UBD Antibody, HRP conjugated	ELISA
FITC	CSB-PA025435LC01HU	UBD Antibody, FITC conjugated
Biotin	CSB-PA025435LD01HU	UBD Antibody, Biotin conjugated	ELISA

克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產品提供形式：

Liquid
應用范圍：

ELISA, IHC, IF

推薦稀釋比：

Application	Recommended Dilution
IHC	1:20-1:200
IF	1:50-1:200

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
Immunofluorescence (IF) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Ubiquitin-like protein modifier which can be covalently attached to target protein and subsequently leads to their degradation by the 26S proteasome, in a NUB1-dependent manner. Probably functions as a survival factor. Conjugation ability activated by UBA6. Promotes the expression of the proteasome subunit beta type-9 (PSMB9/LMP2). Regulates TNF-alpha-induced and LPS-mediated activation of the central mediator of innate immunity NF-kappa-B by promoting TNF-alpha-mediated proteasomal degradation of ubiquitinated-I-kappa-B-alpha. Required for TNF-alpha-induced p65 nuclear translocation in renal tubular epithelial cells (RTECs). May be involved in dendritic cell (DC) maturation, the process by which immature dendritic cells differentiate into fully competent antigen-presenting cells that initiate T-cell responses. Mediates mitotic non-disjunction and chromosome instability, in long-term in vitro culture and cancers, by abbreviating mitotic phase and impairing the kinetochore localization of MAD2L1 during the prometaphase stage of the cell cycle. May be involved in the formation of aggresomes when proteasome is saturated or impaired. Mediates apoptosis in a caspase-dependent manner, especially in renal epithelium and tubular cells during renal diseases such as polycystic kidney disease and Human immunodeficiency virus (HIV)-associated nephropathy (HIVAN).
基因功能參考文獻：
1. the intrinsic instability of FAT10 together with its disordered N-terminus enables the rapid, joint degradation of FAT10 and its substrates. PMID: 30127417
2. Overexpression of FAT10 promotes cisplatinresistant bladder cancer formation. These results indicated FAT10 may be a novel target for the treatment of bladder cancer. PMID: 29749526
3. the results of the present study suggest that FAT10 may be involved in DDR and therefore the progression of tumorigenesis. PMID: 29620277
4. Up-Regulation of UBD Transcript is associated with focal segmental glomerulosclerosis. PMID: 29531077
5. FAT10 promotes tumor proliferation by directly stabilizing Survivin protein in breast cancer cells. PMID: 27806337
6. our data suggest that FAT10 was upregulated via retinoic acid-induced protein I and NF-kappaB during H5N1 avian influenza virus infection. And the upregulated FAT10 promoted H5N1 viral replication by inhibiting type I IFN. PMID: 27354218
7. we show how FAT10 stabilizes the translation elongation factor eEF1A1, which contributes to cancer cell proliferation PMID: 27312528
8. this study revealed a novel function of LMO2 involving in the regulatory hierarchy of UBA6-USE1-FAT10ylation pathway by targeting the E1 enzyme UBA6. PMID: 27569286
9. unlike ISG15, ubiquitin and FAT10 are conjugated to a similar degree to newly translated and pre-existing proteins. PMID: 27926780
10. We also found that FAT10 may act its oncogenic functions through regulating HOXB9. Collectively, the results suggested that FAT10 may be a novel therapeutic target for osteosarcoma patients PMID: 27279480
11. High expression of FAT10 is associated with glioma. PMID: 26733179
12. Study demonstrates how the coordinated interplay of RIG-I, TRIM25, and FAT10 regulate the antiviral innate inflammatory response. PMID: 26996158
13. Data suggest that ubiquitin D (UBD) provides a negative feedback on cytokine-induced activation of the endoplasmic reticulum to nucleus signaling 1 (IRE1alpha)/c-Jun N-terminal kinase (JNK) pro-apoptotic pathway in cytokine-exposed beta cells. PMID: 27044747
14. FAT10 can induce malignant transformation as evidenced from the anchorage-independent growth as well as in vivo tumor-forming abilities of FAT10-overexpressing NeHepLxHT cells. PMID: 24325913
15. repertoire of peptides eluted from MHC class I molecules was influenced by FAT10 expression PMID: 26401002
16. FAT10 is the only ubiquitin-like modifier known to date which directly targets its hundreds of substrates for degradation by the proteasome. (Review) PMID: 25983082
17. Conjugation of the ubiquitin activating enzyme UBE1 with the ubiquitin-like modifier FAT10 targets it for proteasomal degradation PMID: 25768649
18. the interaction of FAT10 with MAD2 is a key mechanism underlying the promalignant property of FAT10 PMID: 25422469
19. Results identified a novel HCC regulatory circuit involving FAT10, beta-catenin/TCF4, and HOXB9, the dysfunction of which drives invasive and metastatic character in HCC. PMID: 25056121
20. STAT3 and NFkappaB synergistically act for maximum induction of FAT10 expression. PMID: 24518302
21. transcription downregulation of the Ufm1 and FAT10 conjugation system in liver Mallory-Denk bodies formation PMID: 24893112
22. functional distribution of the FAT10 targets suggests that FAT10 participates in various biological processes, such as translation, protein folding, RNA processing, and macromolecular complex assembly PMID: 23862649
23. FAT10 expression in pancreatic ductal adenocarcinoma (PDAC) was an independent prognostic factor of patients, which might be a potential diagnostic and therapeutic target of PDAC PMID: 24492942
24. These results suggest that knockdown of FAT10 by adenovirus-delivered siRNA may be a promising therapeutical strategy for treatment of hepatocellular carcinoma. PMID: 24440736
25. FAT10 has a central role in regulating diverse aspects of the pathogenesis of hepatocellular carcinoma. PMID: 23812429
26. FAT10 protects cardiac myocytes against apoptosis. PMID: 23416168
27. Immunohistochemistry showed that FAT10 protein was over-expressed in glioma tissues. Expression level of FAT10 increase from grade I to grade IV glioma according to the results of real-time PCR, immunohistochemistry analysis and Western blot. PMID: 22402871
28. p62 becomes covalently mono-FAT10ylated at several lysines, and FAT10 colocalizes with p62 in p62 bodies. PMID: 22797925
29. FATylation of LRRFIP2 occurs on two distinct sites, each being modified by a single FAT10 moiety. PMID: 23036196
30. These data reveal that VHS domain of Stam2 enters the hydrophobic pocket of K48-linked diubiquitin and binds the two ubiquitin subunits with different affinities. PMID: 21121635
31. This study identified eEF1A1 as a FAT10-specific binding protein, and when the expression of FAT10 was reduced by siRNA knockdown, this resulted in downregulation of eEF1A1 expression in hepatoma cells. PMID: 22569823
32. FAT10 modification of the HCMV-derived antigen pp65 (FAT10-pp65) enhances the presentation of the HLA-A2-restricted pp65495-509 antigenic peptide and provide evidence that FAT10- pp65 differs from Ub-modified pp65 in using the proteasome machinery. PMID: 22349260
33. Ten SNPs in FAT10 were identified. PMID: 22292662
34. Data indicate the potential role of cytokine-induced FAT10 expression in regulating Uba6 pathways. PMID: 22427669
35. findings show how FAT10 and NUB1L dock with the 26S proteasome to initiate proteolysis; identified the 26S proteasome subunit hRpn10/S5a as the receptor for FAT10, whereas NUB1L can bind to both Rpn10 and Rpn1/S2. PMID: 22434192
36. implicate FAT10 in retinal cell biology and Leber congenital amaurosis pathogenesis, and reveal a new role of AIPL1 in regulating the FAT10 pathway. PMID: 22347407
37. In this study a crystal structure of linear diubiquitin at a resolution of 2.2 A degrees is reported. PMID: 22281738
38. Degradation of FAT10 is accelerated after induction of apoptosis, suggesting that it plays a role in prosurvival pathways PMID: 22072791
39. FAT10 plays an important role in mediating the function of TNF-alpha during tumorigenesis by inducing cell cycle deregulation and chromosomal instability. PMID: 22025632
40. An extract of bark from the tropical rainforest plant Byrsonima crassifolia was screened for inhibition of diubiquitin formation by the human ubiquitin-conjugating enzyme E2-25K. PMID: 22164771
41. Data indicate that the 20,000-bp region is telomeric of the UBD gene and contains LOC729653, a hypothetical gene. PMID: 21631897
42. new role for FAT10 in the pathogenesis of polyglutamine diseases. PMID: 21757738
43. The p53 transcriptional activity was found to be substantially enhanced in FAT10-overexpressing cells. PMID: 21396347
44. USE1 is not only the first E2 enzyme but also the first known substrate of FAT10 conjugation, as it was efficiently auto-FAT10ylated in cis but not in trans. PMID: 20975683
45. Genetic polymorphism in UBD is associated with colorectal cancer. PMID: 21351261
46. Reverse transcriptase-polymerase chain reaction analysis of intestinal biopsy sample pairs (at diagnosis vs treated) from 30 celiac disease patients confirmed overexpression of UBD in active disease tissue. PMID: 19808075
47. FAT10 may modulate tumorigenesis through its reported interaction with the MAD2 spindle-assembly checkpoint protein. PMID: 12730673
48. FAT10 is degraded by the proteasome in ubiqitin-independent manner. PMID: 15831455
49. high levels of FAT10 protein in cells lead to increased mitotic nondisjunction and chromosome instability, which is mediated by an abbreviated mitotic phase and reduction in the kinetochore localization of MAD2 during prometaphase PMID: 16495226
50. Immunohistochemical studies demonstrated increased FAT10 expression in HIV-associated nephropathy and in autosomal dominant polycystic kidney disease. PMID: 16495380
顯示更多

收起更多
亞細胞定位：

Nucleus. Cytoplasm. Note=Accumulates in aggresomes under proteasome inhibition conditions.
組織特異性：

Constitutively expressed in mature dendritic cells and B-cells. Mostly expressed in the reticuloendothelial system (e.g. thymus, spleen), the gastrointestinal system, kidney, lung and prostate gland.
數據庫鏈接：

HGNC: 18795

OMIM: 606050

KEGG: hsa:10537

STRING: 9606.ENSP00000366249

UniGene: Hs.44532

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human